Linear IgA bullous dermatosis and elevated bullous interleukin-6 levels: Responsive to treatment with Anti-IL-6 receptor monoclonals

Stanley C Jordan; Bonnie Balzer; Cynthia Nast; Janet Atienza; Katherine Lim; Sanjeev Kumar; Nicholas Nissen; Bongha Shin

doi:10.1002/ccr3.6998

Linear IgA bullous dermatosis and elevated bullous interleukin-6 levels: Responsive to treatment with Anti-IL-6 receptor monoclonals

Clin Case Rep. 2023 Feb 27;11(2):e6998. doi: 10.1002/ccr3.6998. eCollection 2023 Feb.

Authors

Stanley C Jordan^{1

2}, Bonnie Balzer³, Cynthia Nast³, Janet Atienza¹, Katherine Lim¹, Sanjeev Kumar¹, Nicholas Nissen¹, Bongha Shin^{1

2}

Affiliations

¹ Comprehensive Transplant Center Cedars-Sinai Medical Center Los Angeles California USA.
² Transplantation & Immunology Laboratory Cedars-Sinai Medical Center Los Angeles California USA.
³ Department of Pathology & Laboratory Medicine Cedars-Sinai Medical Center Los Angeles California USA.

Abstract

Linear IgA bullous dermatosis (LABD) is a rare autoimmune/inflammatory skin condition. Here, we report on a patient who developed treatment resistant LABD. At diagnosis, elevations of IL-6 and C-reactive protein in the blood and extreme elevations of IL-6 in LABD bullous fluid were seen. The patient responded well to tocilizumab (anti-IL-6 receptor) treatment.

Keywords: IgA bullous dermatosis; anti‐IL‐6 receptor antibody; interleukin 6; kidney transplant; pancreatic cancer.

Publication types

Case Reports